A Phase 2 clinical trial of PF-05212377 (SAM-760) in subjects with mild to moderate Alzheimer’s disease with existing neuropsychiatric symptoms on a stable daily dose of donepezil

A Phase 2 clinical trial of PF-05212377 (SAM-760) in subjects with mild to moderate Alzheimer’s disease with existing neuropsychiatric symptoms on a stable daily dose of donepezil

Abstract Background Symptomatic benefits have been reported for 5-HT6 receptor antagonists in Alzheimer’s disease (AD) trials. SAM-760 is a potent and selective 5-HT6 receptor antagonist that has demonstrated central 5-HT6 receptor saturation in humans at a dose of 30 mg. Methods This was a randomiz...

Full description

Bibliographic Details
Main Authors: Terence Fullerton, Brendon Binneman, William David, Marielle Delnomdedieu, James Kupiec, Peter Lockwood, Jessica Mancuso, Jeffrey Miceli, Joanne Bell
Format: Article
Language:English
Published: BMC 2018-04-01
Series:Alzheimer’s Research & Therapy
Subjects:
Alzheimer’s Disease
Serotonin
5-HT
Online Access:http://link.springer.com/article/10.1186/s13195-018-0368-9

Internet

http://link.springer.com/article/10.1186/s13195-018-0368-9

Similar Items